Biotech Stocks Pressured (BIIB) (CELG) (GILD)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Oil rises on Iran war stalemate; near-term potential for further gains seen limited
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
Celladon Reports Negative Results for CUPID2 Trial of MYDICAR(R) in Advanced Heart Failure
April 26, 2015 4:41 PM EDT- Investigational gene therapy fails to meet primary and secondary endpoints - - Investor conference call and webcast Monday at 8:30 a.m. ET (5:30 a.m. PT) -
SAN DIEGO, April 26, 2015 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq: CLDN) today announced that its Phase 2b CUPID2 trial did not meet its primary and secondary endpoints. CUPID2 is a randomized, double-blind, placebo-controlled, multinational trial evaluating a single, one-time, intracoronary infusion of the cardiovascular gene therapy agent MYDICAR® (AAV1/SERCA2a) versus placebo added to a maximal, optimized heart failure drug... More
